Journal
AGING-US
Volume 12, Issue 15, Pages 15670-15681Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/aging.103770
Keywords
COVID-19; lactate dehydrogenase; risk factor; severity; mortality
Categories
Funding
- National Natural Science Foundation of China [81670815]
- Guangdong Basic and Applied Basic Research Foundation [2020A1515010124]
- Special Fund for Innovation Strategy of Science and Technology Plan of Guangdong Province [2019A030317011]
Ask authors/readers for more resources
Early identification of severe patients with coronavirus disease 2019 (COVID-19) is very important for individual treatment. We included 203 patients with COVID-19 by propensity score matching in this retrospective, case-control study. The effects of serum lactate dehydrogenase (LDH) at admission on patients with COVID-19 were evaluated. We found that serum LDH levels had a 58.7% sensitivity and 82.0% specificity, based on a best cut-off of 277.00 U/L, for predicting severe COVID-19. And a cut-off of 359.50 U/L of the serum LDH levels resulted in a 93.8% sensitivity, 88.2% specificity for predicting death of COVID-19. Additionally, logistic regression analysis and Cox proportional hazards model respectively indicated that elevated LDH level was an independent risk factor for the severity (HR: 2.73, 95% CI: 1.25-5.97; P=0.012) and mortality (HR: 40.50, 95% CI: 3.65-449.28; P=0.003) of COVID-19. Therefore, elevated LDH level at admission is an independent risk factor for the severity and mortality of COVID-19. LDH can assist in the early evaluating of COVID-19. Clinicians should pay attention to the serum LDH level at admission for patients with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available